GNLX vs. RXRX

Last updated Apr 2, 2026

Compare and contrast key facts about Genelux Corporation (GNLX) and Recursion Pharmaceuticals, Inc. (RXRX).

Performance

GNLX vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Genelux Corporation (GNLX) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

GNLX vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023
GNLX Genelux Corporation	-41.28%	84.75%	-83.15%	127.80%
RXRX Recursion Pharmaceuticals, Inc.	-25.18%	-39.50%	-31.44%	20.39%

Fundamentals

Market Cap GNLX : $95.17M RXRX : $1.61B
EPS GNLX : -$0.85 RXRX : -$1.39
PS Ratio GNLX : 12.06K RXRX : 19.03
PB Ratio GNLX : 8.24 RXRX : 1.43
Total Revenue (TTM) GNLX : $8.00K RXRX : $74.56M
Gross Profit (TTM) GNLX : $0.00 RXRX : $3.73M
EBITDA (TTM) GNLX : $0.00 RXRX : -$579.69M

Returns By Period

In the year-to-date period, GNLX achieves a -41.28% return, which is significantly lower than RXRX's -25.18% return.

GNLX

• 1D: 5.79%
• 1M: -12.33%
• YTD: -41.28%
• 6M: -41.82%
• 1Y: -1.54%
• 3Y*: -54.81%
• 5Y*: —
• 10Y*: —

RXRX

• 1D: -0.33%
• 1M: -15.70%
• YTD: -25.18%
• 6M: -40.00%
• 1Y: -39.94%
• 3Y*: -22.87%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GNLX vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNLX

GNLX Risk / Return Rank: 41
GNLX Sharpe Ratio Rank: 39
GNLX Sortino Ratio Rank: 45
GNLX Omega Ratio Rank: 45
GNLX Calmar Ratio Rank: 38
GNLX Martin Ratio Rank: 38

RXRX

RXRX Risk / Return Rank: 18
RXRX Sharpe Ratio Rank: 19
RXRX Sortino Ratio Rank: 22
RXRX Omega Ratio Rank: 23
RXRX Calmar Ratio Rank: 15
RXRX Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNLX vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Genelux Corporation (GNLX) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GNLX	RXRX	Difference
Sharpe ratio Return per unit of total volatility	-0.02	-0.48	+0.46
Sortino ratio Return per unit of downside risk	0.66	-0.32	+0.98
Omega ratio Gain probability vs. loss probability	1.09	0.97	+0.13
Calmar ratio Return relative to maximum drawdown	-0.07	-0.72	+0.65
Martin ratio Return relative to average drawdown	-0.14	-1.43	+1.29
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

GNLX vs. RXRX - Sharpe Ratio Comparison

The current GNLX Sharpe Ratio is -0.02, which is higher than the RXRX Sharpe Ratio of -0.48. The chart below compares the historical Sharpe Ratios of GNLX and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	GNLX	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.02	-0.48	+0.46
Sharpe Ratio (All Time) Calculated using the full available price history	-0.21	-0.40	+0.18

Correlation

The correlation between GNLX and RXRX is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GNLX vs. RXRX - Dividend Comparison

Neither GNLX nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

GNLX vs. RXRX - Drawdown Comparison

The maximum GNLX drawdown since its inception was -95.74%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for GNLX and RXRX.

Drawdown Indicators

	GNLX	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	-95.74%	-93.13%	-2.61%
Max Drawdown (1Y) Largest decline over 1 year	-72.09%	-58.17%	-13.92%
Current Drawdown Current decline from peak	-93.26%	-92.60%	-0.66%
Average Drawdown Average peak-to-trough decline	-72.07%	-74.78%	+2.71%
Ulcer Index Depth and duration of drawdowns from previous peaks	37.89%	29.48%	+8.41%

Volatility

GNLX vs. RXRX - Volatility Comparison

Genelux Corporation (GNLX) has a higher volatility of 19.30% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 14.66%. This indicates that GNLX's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GNLX	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.30%	14.66%	+4.64%
Volatility (6M) Calculated over the trailing 6-month period	75.07%	54.53%	+20.54%
Volatility (1Y) Calculated over the trailing 1-year period	93.70%	83.97%	+9.73%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	113.14%	94.52%	+18.62%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	113.14%	94.52%	+18.62%

Financials